Labshake search
Citations for TargetMol :
1 - 9 of 9 citations for Mouse anti Plasmodium vivax CSP PVC 2 since 2019
Citations are collected from bioRxiv only, the total number of publications could be much larger.
-
bioRxiv - Systems Biology 2022Quote: ... AKT1-2 inhibitor MK-2206 (Targetmol, 1032350-13-2), and everolimus (Targetmol ...
-
bioRxiv - Biophysics 2022Quote: ... Ara-C (2 mM, TargetMol, T1272) was added to the medium to inhibit neural stem cell proliferation ...
-
bioRxiv - Systems Biology 2022Quote: ... including lapatinib (Targetmol, 231277-92-2), AKT1-2 inhibitor MK-2206 (Targetmol ...
-
bioRxiv - Biophysics 2022Quote: ... and 2 mg/ml doxycycline (TargetMol, T1687). On day 1 ...
-
bioRxiv - Cell Biology 2021Quote: WIN 55,212-2 mesylate was purchased from TargetMol (T4458). Stock solutions were prepared using 100% dimethyl sulfoxide (DMSO ...
-
bioRxiv - Cancer Biology 2019Quote: ... cells were pre-treated with Afatinib (2 μM; T2303, TargetMol) or LY2157299 (10 μM ...
-
bioRxiv - Cancer Biology 2023Quote: ... 20-24 mice whose tumor volume had reached ∼250 mm3 (mouse grafts) or ∼80 mm3 (human grafts) at week two after grafting received either 10 mg/kg enzalutamide (TargetMol T6002) or 0.5% DMSO (MilliporeSigma D2650 ...
-
bioRxiv - Neuroscience 2023Quote: ... and 5-(3-Bromophenyl)-1,3-dihydro-2H-benzofuro[3,2-e]-1,4-diazepin-2-one (5-BDBD) (cat. no. T22518, TargetMol, Wellesley Hills, Massachusetts, USA) were dissolved in stock solutions and then diluted into ACSF at specified concentrations (50 µM IVM ...
-
bioRxiv - Pathology 2021Quote: A compound library including 315 approved anti-cancer drugs was purchased from TargetMol (L2110 ...